Contact us

Get in touch

Reach out via email to schedule a meeting with our team. If you’re an investor interested in exploring opportunities, we’ll get back to you.

stem@ipsirius.com

Hello, I’m

Reach me at

Type here

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Frequently asked questions

General

Can't find your answer?

What is iPSirius ?

iPSirius is a French biotechnology company specializing in the development of innovative cancer immunotherapies. Using cutting-edge iPVAC technology, we create off-the-shelf cancer vaccines based on induced pluripotent stem cells (iPSCs).

What is iPVAC technology ?

iPVAC is our proprietary technology that uses iPSCs to develop cancer vaccines. These vaccines are designed to stimulate the immune system and target aggressive tumors, including non-immunogenic solid tumors.

What types of cancer does iPSirius focus on ?

Our primary focus is on aggressive cancers, such as non-small-cell lung cancer (NSCLC), where innovative treatments can significantly improve patient outcomes.

What makes iPSirius different from other companies in the field ?

iPSirius is a pioneer in using iPSC-based technologies to create off-the-shelf cancer vaccines. With a strong patent portfolio and a visionary team, we are addressing key challenges in oncology and delivering accessible, innovative immunotherapies.

Has iPSirius received any recognition or funding ?

iPSirius was awarded the prestigious EIC Pathfinder Award from the European Innovation Council, securing $2M in funding to accelerate our clinical development.

Are iPSirius vaccines currently available to patients ?

Our vaccines are in the preclinical development phase. Our first-in-human clinical trial will start in 2026.

Contact us

Get in touch

Frequently asked questions

Pages

Social

Contact us